View Older Stories

Aug 25, 2026 04:44PM Court awards Biohaven and Yale $4M in trade secret case

Aug 11, 2026 10:02AM Biohaven Pharma (BHVN) PT Raised to $23 at RBC Capital

Aug 10, 2026 04:24PM Biohaven Pharma (BHVN) Misses Q2 EPS by 3c

Jul 27, 2026 07:01AM Jury awards Biohaven and Yale $4M in trade secret case

Jul 9, 2026 05:01PM Biohaven names new discovery head as CSO shifts to part-time role

Jun 30, 2026 07:31AM Biohaven completes enrollment in focal epilepsy drug trial

Jun 29, 2026 03:27PM Biohaven Pharma (BHVN) call put ratio 7.5 calls to 1 put as share price down 4.7%

Jun 29, 2026 06:13AM BofA Securities Downgrades Biohaven Pharma (BHVN) to Underperform

Jun 17, 2026 10:15AM Increasing unusual option volume: BHVN DOMO CLPT OIH CVLT PEGA OTLK VT

Jun 1, 2026 07:31AM Biohaven begins first human trial of brain-penetrant drug BHV-8100

May 27, 2026 10:16AM Raymond James on Biohaven Pharma (BHVN) with shares up 7%: 'Promising Degrader Data Sets Ahead of R&D Day'

May 27, 2026 07:31AM Biohaven reports positive patient data for autoimmune disease drugs

May 26, 2026 07:31AM Biohaven shares clinical data on epilepsy drug opakalim

May 12, 2026 06:52AM H.C. Wainwright Reiterates Neutral Rating on Biohaven Pharma (BHVN)

May 4, 2026 05:11PM Biohaven Pharma (BHVN) Misses Q1 EPS by 4c

May 4, 2026 04:26PM Biohaven Pharma (BHVN) files mixed shelf

Apr 13, 2026 05:18AM Canaccord Starts Biohaven Pharma (BHVN) at Buy

Apr 2, 2026 05:09AM Biohaven Pharma (BHVN) PT Raised to $17 at Citi

Mar 16, 2026 05:28PM Biohaven Pharma (BHVN) PT Raised to $28 at Jefferies

Mar 9, 2026 01:55PM Raymond James on Biohaven Pharma (BHVN): 'results continue to highlight an opportunity for opakalim'

Mar 4, 2026 06:45AM Biohaven Pharma (BHVN) PT Lowered to $10 at H.C. Wainwright

Mar 3, 2026 02:43PM Leerink Partners Reiterates Outperform Rating on Biohaven Pharma (BHVN), lowers EPS estimates

Mar 3, 2026 09:01AM Biohaven Pharma (BHVN) PT Raised to $23 at RBC Capital

Mar 3, 2026 08:43AM Piper Sandler: 'Biohaven Pharma (BHVN) Gearing Up for a Catalyst-Rich 2026'

Mar 2, 2026 08:18PM Biohaven Pharma (BHVN) Tops Q4 EPS by 28c

Feb 23, 2026 08:43AM Piper Sandler on Biohaven Pharma (BHVN): 'We like the risk/reward at current levels'

Feb 5, 2026 04:21PM Goldman Sachs Starts Biohaven Pharma (BHVN) at Buy

Jan 21, 2026 05:04AM RBC Capital Upgrades Biohaven Pharma (BHVN) to Outperform

Jan 12, 2026 01:44PM Bairdon Biohaven (BHVN): 'e think case studies from today's presentation answers the major question lingering for BHV-1400'

Jan 12, 2026 11:20AM Biohaven reports early patient data from protein degrader programs

Dec 26, 2025 08:18AM Stifel Reiterates Xenon Pharmaceuticals (XENE) at Buy following Biohaven's failure

Dec 26, 2025 06:40AM H.C. Wainwright Reiterates Neutral Rating on Biohaven Pharmaceutical Holding (BHVN)

Dec 26, 2025 06:08AM Biohaven Pharma (BHVN) call put ratio 1 call to 1 put as share price lower before the bell

Dec 11, 2025 07:02AM Biohaven shares cancer drug trial results at European oncology meeting

Dec 3, 2025 06:07AM H.C. Wainwright Downgrades Biohaven Pharmaceutical Holding (BHVN) to Neutral

Nov 26, 2025 04:18AM UBS Downgrades Biohaven Pharmaceutical Holding (BHVN) to Neutral

Nov 17, 2025 07:38AM Biohaven Pharmaceutical Holding (BHVN) PT Lowered to $26 at Morgan Stanley

Nov 12, 2025 08:35AM Biohaven Pharmaceutical Holding (BHVN) PT Lowered to $14 at Citi

Nov 11, 2025 04:29AM William Blair Reiterates Market Perform Rating on Biohaven Pharmaceutical Holding (BHVN)

Nov 10, 2025 07:40AM Biohaven Pharma (BHVN) Tops Q3 EPS by 24c

Nov 6, 2025 08:37AM Piper Sandler Slashes Biohaven Pharmaceutical (BHVN) Stock PT as 'FDA Says No to Troriluzole'

Nov 6, 2025 02:23AM Bernstein SocGen Group Downgrades Biohaven Pharmaceutical Holding (BHVN) to Market Perform

Nov 5, 2025 04:09PM Biohaven Pharmaceutical Holding (BHVN) PT Lowered to $15 at Leerink Partners

Nov 5, 2025 03:33PM BofA Securities Downgrades Biohaven Pharmaceutical Holding (BHVN) to Neutral

Nov 5, 2025 10:51AM Raymond James Comments on Biohaven (BHVN) Post Management Call

Nov 5, 2025 10:00AM William Blair Downgrades Biohaven Pharmaceutical Holding (BHVN) to Market Perform

Nov 5, 2025 08:20AM JPMorgan on Biohaven Pharmaceutical (BHVN): 'expect the stock to be under some pressure'

Nov 5, 2025 08:19AM William Blair on Biohaven (BHVN): 'Expect Weakness'

Nov 5, 2025 08:17AM Morgan Stanley on Biohaven (BHVN): 'The next catalyst for the stock is Opakalim (BHV-7000; Kv7 activator) Ph2/3 data in major depressive disorder (MDD)'

Nov 5, 2025 08:16AM Raymond James on Biohaven Pharmaceutical Holding (BHVN): 'Meaningful Value Remains', 'Sticking with it'

View Older Stories